Wall St futures steady after extended losses on Nvidia, payrolls caution
Investing.com - BTIG raised its price target on Establishment Labs Holdings Inc. (NASDAQ:ESTA) to $70.00 from $62.00 while maintaining a Buy rating, citing the company’s strong Q3 performance and positive outlook. The new target represents potential upside from ESTA’s current price of $61.78, which has already surged past its previous 52-week high of $54.06. According to InvestingPro data, analysts maintain a Strong Buy consensus on the stock.
Establishment Labs reported Q3 revenue of $53.8 million, representing 33.8% year-over-year growth and exceeding consensus estimates by $1.6 million. U.S. sales reached $11.9 million, also surpassing the consensus expectation of $11.2 million. This performance continues the company’s solid revenue growth trajectory, with InvestingPro data showing 17.22% revenue growth over the last twelve months for the $1.78 billion market cap company.
The company achieved positive adjusted EBITDA of $1.2 million for the first time and remains focused on reaching cash flow positive status next year. Management raised its full-year 2025 sales outlook to exceed $210 million, above the midpoint of its previous guidance range of $208-212 million. This milestone is significant as InvestingPro data indicates the company is not yet profitable over the last twelve months, with analysts not expecting profitability this year. ESTA’s strong liquidity position is reflected in its healthy current ratio of 2.84, indicating liquid assets exceed short-term obligations.
ESTA now anticipates U.S. Motiva revenue to meaningfully exceed $40 million, with the company exiting 2025 with approximately 20% share of the U.S. breast augmentation market. This exit rate is well above BTIG’s prior estimate of 16% share in Q4.
The company confirmed timelines remain on track for the U.S. launch of Preservé in the first half of 2026 and FDA submission for the breast reconstruction label expansion by year-end, with management reiterating that Mia and Preservé together will exceed $30 million in worldwide revenue in 2026.
In other recent news, Establishment Labs Holdings Inc . reported its third-quarter 2025 earnings, exceeding analyst expectations. The company posted an earnings per share (EPS) of -$0.38, which was better than the forecasted -$0.51, marking a positive surprise of 25.49%. Additionally, Establishment Labs reported revenue of $53.8 million, surpassing the anticipated $52.25 million. These results highlight the company’s stronger-than-expected performance in the quarter. Analysts had projected lower figures, but the actual outcomes were more favorable. The earnings announcement was followed by positive investor sentiment. These developments are part of the latest updates concerning Establishment Labs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.